Literature DB >> 10544612

[Pathophysiologic significance of growth factors and new therapeutic concepts in cardiovascular disease].

S Rosenkranz1, M Böhm, A Kazlauskas.   

Abstract

Peptide growth factors such as PDGF, FGF, VEGF, and TGF-beta play a critical role in the pathogenesis of cardiovascular diseases. In addition to their pathophysiological role in atherosclerosis and myocardial remodeling, growth factors also promote beneficial effects such as stimulation of angiogenesis and formation of collateral vessels in ischemic tissue. This review focuses on the mechanisms of action and signal relay cascades of peptide growth factors, and summarizes novel therapeutic approaches in cardiovascular medicine. These approaches include both inhibition of growth factors in order to suppress pathogenic processes, and stimulation of growth factors to promote their beneficial effects.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10544612     DOI: 10.1007/bf03044941

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  113 in total

1.  Vascular permeability factor accelerates endothelial regrowth following balloon angioplasty.

Authors:  A D Callow; E T Choi; J D Trachtenberg; S L Stevens; D T Connolly; C Rodi; U S Ryan
Journal:  Growth Factors       Date:  1994       Impact factor: 2.511

2.  Negative inotropic effect of basic fibroblast growth factor on adult rat cardiac myocyte.

Authors:  Y Ishibashi; Y Urabe; H Tsutsui; S Kinugawa; M Sugimachi; M Takahashi; S Yamamoto; H Tagawa; K Sunagawa; A Takeshita
Journal:  Circulation       Date:  1997-10-21       Impact factor: 29.690

3.  Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia.

Authors:  I Baumgartner; A Pieczek; O Manor; R Blair; M Kearney; K Walsh; J M Isner
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

4.  Basic fibroblast growth factor enhances myocardial collateral flow in a canine model.

Authors:  E F Unger; S Banai; M Shou; D F Lazarous; M T Jaklitsch; M Scheinowitz; R Correa; C Klingbeil; S E Epstein
Journal:  Am J Physiol       Date:  1994-04

5.  Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells.

Authors:  D A Linseman; C W Benjamin; D A Jones
Journal:  J Biol Chem       Date:  1995-05-26       Impact factor: 5.157

6.  Inhibition of angiogenesis by suramin.

Authors:  A Gagliardi; H Hadd; D C Collins
Journal:  Cancer Res       Date:  1992-09-15       Impact factor: 12.701

7.  Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor.

Authors:  A Yanagisawa-Miwa; Y Uchida; F Nakamura; T Tomaru; H Kido; T Kamijo; T Sugimoto; K Kaji; M Utsuyama; C Kurashima
Journal:  Science       Date:  1992-09-04       Impact factor: 47.728

8.  Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor.

Authors:  R Baffour; J Berman; J L Garb; S W Rhee; J Kaufman; P Friedmann
Journal:  J Vasc Surg       Date:  1992-08       Impact factor: 4.268

9.  Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only.

Authors:  E Brogi; T Wu; A Namiki; J M Isner
Journal:  Circulation       Date:  1994-08       Impact factor: 29.690

10.  Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells.

Authors:  G T Stavri; Y Hong; I C Zachary; G Breier; P A Baskerville; S Ylä-Herttuala; W Risau; J F Martin; J D Erusalimsky
Journal:  FEBS Lett       Date:  1995-01-30       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.